이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
CytomX Therapeutics 관리
관리 기준 확인 3/4
CytomX Therapeutics' CEO는 Sean McCarthy, Aug2011 에 임명되었습니다 의 임기는 12.83 년입니다. 총 연간 보상은 $ 2.61M, 25% 로 구성됩니다. 25% 급여 및 75% 보너스(회사 주식 및 옵션 포함). 는 $ 683.58K 가치에 해당하는 회사 주식의 0.68% 직접 소유합니다. 683.58K. 경영진과 이사회의 평균 재임 기간은 각각 3.2 년과 4.4 년입니다.
주요 정보
Sean McCarthy
최고 경영자
US$2.6m
총 보상
| CEO 급여 비율 | 25.0% |
| CEO 임기 | 12.9yrs |
| CEO 소유권 | 0.7% |
| 경영진 평균 재임 기간 | 3.3yrs |
| 이사회 평균 재임 기간 | 4.5yrs |
최근 관리 업데이트
Recent updates
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
Jun 15
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now
May 09CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
May 02CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Checking In On CytomX Therapeutics
Jun 13Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being
Jun 10CytomX EPS beats by $0.06, misses on revenue
May 06Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%
Mar 25CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$3m | US$652k | -US$569k |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$42m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$3m | US$623k | -US$99m |
| Sep 30 2022 | n/a | n/a | -US$149m |
| Jun 30 2022 | n/a | n/a | -US$143m |
| Mar 31 2022 | n/a | n/a | -US$132m |
| Dec 31 2021 | US$4m | US$616k | -US$116m |
| Sep 30 2021 | n/a | n/a | -US$72m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$3m | US$595k | -US$65m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$76m |
| Dec 31 2019 | US$4m | US$575k | -US$133m |
| Sep 30 2019 | n/a | n/a | -US$99m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$83m |
| Dec 31 2018 | US$5m | US$550k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$52m |
| Jun 30 2018 | n/a | n/a | -US$39m |
| Mar 31 2018 | n/a | n/a | -US$50m |
| Dec 31 2017 | US$3m | US$500k | -US$43m |
보상 대 시장: Sean 의 총 보상 ($USD 2.61M )은 US 시장( $USD 683.56K ).
보상과 수익: Sean 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Sean McCarthy (57 yo)
12.9yrs
테뉴어
US$2,611,138
보상
Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since August 2021. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been it...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman & CEO | 12.9yrs | US$2.61m | 0.68% $ 646.5k | |
| Senior VP & Chief Scientific Officer | 1.5yrs | US$1.21m | 0.076% $ 72.5k | |
| Senior VP | 3.3yrs | US$1.05m | 0.068% $ 64.6k | |
| Chief Financial Officer | 1.8yrs | 데이터 없음 | 0.033% $ 31.0k | |
| Senior VP | 6.2yrs | US$1.21m | 0.083% $ 79.1k | |
| Senior VP & Chief Human Resources Officer | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Intellectual Property | 5.4yrs | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Quality & Product Manufacturing | 1.5yrs | 데이터 없음 | 데이터 없음 | |
| Special Advisor to Chief Executive Officer | no data | US$273.54k | 데이터 없음 |
3.3yrs
평균 재임 기간
55.5yo
평균 연령
경험이 풍부한 관리: CTMX 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman & CEO | 12.9yrs | US$2.61m | 0.68% $ 646.5k | |
| Independent Director | 5.2yrs | US$75.12k | 0.0066% $ 6.3k | |
| Member of Scientific Advisory Board | 4.5yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 3.6yrs | US$78.62k | 0% $ 0 | |
| Independent Director | 5.6yrs | US$77.12k | 0% $ 0 | |
| Lead Independent Director | 8.8yrs | US$105.12k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$80.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.6yrs | US$8.03m | 데이터 없음 | |
| Independent Director | 2.8yrs | US$69.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.5yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 1.5yrs | 데이터 없음 | 데이터 없음 |
4.5yrs
평균 재임 기간
61yo
평균 연령
경험이 풍부한 이사회: CTMX 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.